Added to YB: 2026-10-09
Pitch date: 2026-10-04
SVRA [bullish]
Savara Inc.
-2.27%
current return
Author Info
No bio for this author
Company Info
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
Market Cap
$1.2B
Pitch Price
$4.85
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.60
P/E
-8.35
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - Savara Inc.
SVRA (hold): Savara’s molgramostim, an inhaled GM-CSF therapy for autoimmune pulmonary alveolar proteinosis, is under FDA Priority Review, with the review extended three months to a November 22, 2026 PDUFA date. The asset could fit a rare-pulmonary buyer with existing specialist infrastructure, but the limited population narrows the buyer universe, while approval, label, reimbursement, patient identification and launch economics remain unproven.
Read full article (1 min)